

References

- 1-El-Refaey H and Rodec C(2003):** Postpartum hemorrhage:definitions, medical and surgical management. A time for change. Br Med. Bull; 67:205-17.
- 2-Cunningham FG, Gant NF, Leveno KJ, Glistrap LC, Hauth JC and Wenstorm KD (2001):** Conduct of normal labor and delivery. Williams's obstetrics 21st Edition published by Mc Graw-Hill Companies Inc; USA, P: 309-92.
- 3- World Health Organization (2004):** Maternal Mortality in 2000: Estimates developed by WHO, UNICEF and UNFPA.
- 4-World Health Organization(1998):** Postpartum care of the mother and the newborn: A practical Guide. Geneva: WHO safe Motherhood Unit.
- 5-Chong YS, Su LL and Arulkumaran S (2004):** Current strategies for the prevention of postpartum hemorrhage in the third stage of labor. Curr Opin Obstet Gynecol; 16(2): 143-50.
- 6-Prendiville WJ, Elbourne D and McDonald S (1997):** Active versus expectant management of the third stage of labor. In: Neilson JP, Corwther CA, Hodnett E, Hofmeyr GJ, Kerise MJ, editors. Pregnancy and child birth module of the Cochrane database of systematic reviews. The Cochrane collaboration: issue 1. Oxford:Update Software.
- 7-Langenbach C (2006):** Misoprostol in preventing postpartum hemorrhage: A meta-analysis. Inter J Gynecol Obstet; 92: 10-18.
- 8-Tsu VD, Langer A and Aldrich T (2004):** Postpartum hemorrhage in developing countries: is the public health community using the right tools? Int J Gynecol Obstet; 85(Supp1): S42-51.

9-World Health Organization(1997): Coverage of Maternity Care: a listing of available information. Fourth edition.

10-Roman AS and Andrei R (2003): Seven ways to control postpartum hemorrhage. *Contemp OB/GYN*; 3: 34-53.

11-Gregson S, Waterstone M, Norman I and Murrells T (2005): A randomised controlled trial comparing low dose vaginal misoprostol and dinoprostone vaginal gel for inducing labor at term. *BJOG*; 112(4): 438-44.

12-Nguyen TN, Blum J, Durocher J, Quan TT and Winikoff B (2005): A randomized controlled study comparing 600 versus 1200 µg oral misoprostol for medical management of incomplete abortion. *Contraception*; 72(6): 438-42.

13-Kapp N, Borgatta L, Ellis SC, Vragovic O and Stubblefield P (2005): Simultaneous low-dose mifepristone and vaginal misoprostol for medical abortion. *BJOG*; 105(4): 57S.

14-Oboro VO and Tabowei TO (2005): Outpatient misoprostol cervical ripening without subsequent induction of labor to prevent post-term pregnancy. *Acta Obstet Gynecol Scand*; 84: 628-31.

15-El-Refaey H and Templeton A (1994): Early abortion induction by a combination of mifepristone and oral misoprostol. Acomparision between 2 dose regimens of misoprostol and their effect on blood pressure. *BJOG*; 101: 792-796.

16-El-Refaey H, Obrien P, Marafa W, Walder J and Rodeck C (1996): Misoprostol for the third stage of labor. *Lancet*; 347(5): 1257.

17-Miller S, Lester F and Hensleigh P (2004): Prevention and treatment of postpartum hemorrhage: new advances for low-resource settings. *J Midwifery women´s Health*; 49(4): 283-92.

- 18-Joy SD, Sanchez-Ramos L and Kaunitz AM (2003):** Misoprostol use during the third stage of labor. *Int J Gynecol Obstet*; 82(2): 143-52.
- 19-Tang OS, Schweer H, Seyberth HW, Sharon HW, Lee SW and Ho PC (2002):** Pharmacokinetics of different routes of administration of misoprostol. *Hum Reprod*; 17(2): 332-6.
- 20-Berg CJ, Atrash HK, Koonin LM and Tucker M (1996):** Pregnancy-related mortality in the United States, 1987-1990. *Obstet Gynecol*; 88(2):161-7.
- 21-Abou Zahr C (1998):** Antepartum and postpartum hemorrhage. In: Murray CJ, Lopez AD, eds. *Health Dimensions of Sex and Reproduction*. Boston, Mass: Harvard University Press; P: 172-81.
- 22-American College of Obstetricians and Gynecologists. ACOG Practice Bulletin (2006):** Clinical Management Guidelines for Obstetrician-Gynecologists Number 76, October 2006: postpartum hemorrhage. *Obstet Gynecol*;108(4):1039-47.
- 23-Cunningham FG, Gant NF, Leveno KJ, Gilstrap LC, Hauth JC and Wenstorm KD (2001):** Maternal adaptation to pregnancy. Chapter 8 in *Williams Obstetrics 21st edition*. Editor: McGraw-Hill; P: 167-75.
- 24-Baskett TF (1999):** Complications of the third stage of labor. In: *Essential Management of Obstetrical Emergencies*. 3rd ed. Bristol, UK: Clinical Press; P: 196-201.
- 25-Combs CA and Larros RK (1991):** Prolonged third stage of labor morbidity and risk factors. *Obstet Gynecol*; 77: 863-67.
- 26-Pierre LG, Jacques V, Jean PD, Baulat P, Bernard H and Laffargue F (2000):** A randomized evaluation of two techniques of management of the third stage of labor in woman at low risk of postpartum hemorrhage. *BJOG*; 107: 396-400.



- 27-Bais JM, Eskes M, Pel M, Bonsel GJ, and Bleker OP (2004):** Postpartum hemorrhage in nulliparous women: incidence and risk factors in low and high risk women. A Dutch population-based cohort study on standard ($> \text{Or} = 500 \text{ ml}$) and severe ($> \text{or} = 1000 \text{ ml}$) postpartum hemorrhage. *Eur J Obstet Gynecol Reorod Biol*; 115(2): 166-72.
- 28-Magann EF and Lanneau GS (2005):** Third stage of labor. *Obstet Gynecol Clin North Am*; 32(2): 323-32.
- 29-Cunningham FG, Leveno KJ, Hauth JC, Gilstrap LC and Wenstorm KD (2005):** Normal labor and delivery. Volume (1) chapter 17 in *Williams Obstetrics 22nd edition*. Editor: P: 430-5.
- 30-Prendiville W, Elbourne D and Chalmers J (1988):** The effect of routine oxytocin administration in the management of third stage of labor. *BRJ*; 197:1295-300.
- 31-Wilson JR and Stillwill D (1996):** Delivery of the placenta. *Med Illust Atlas of obstetric techniques 2nd ed*. St Louis, Mo: Mosby: P: 264.
- 32-Cunningham FG, Leveno KJ, Gant NF, Alexander JM, Bloom SL, Casey BM, Dashe JS, Sheffield JS and Yost ND (2003):** Hemorrhage immediately following delivery. *Williams's manual of obstetrics 21st Edition* published by the MC Graw-Hill Companies Inc; USA, P: 377-92.
- 33-Blanchette H (1977):** Elective manual exploration of the uterus after delivery: a study and review. *J Reprod Med*; 19:13.
- 34-McDonald S, Prendiville W and Blair (1993):** Randomized controlled trial of oxytocin alone versus oxytocin and ergometrine in active management of the third stage of labor. *BMJ*; 307:1167-71.
- 35-Prendiville WJ, Elbourne D and McDonald S (2002):** Active versus expectant management in the third stage of labor (Cochrane Review). In: *The Cochrane Library, Issue 2*. Oxford, UK: Update Software.



36-McDonald S, Prendiville WJ Elbourne D (2002): Prophylactic syntometrine versus oxytocin for delivery of the placenta (Cochrane Review). In: The Cochrane Library, Issue 2. Oxford, UK: Update Software.

37-Begley CM (1990): A comparison of 'active' and 'physiological' management of the third stage of labour. *Midwifery*;6(1):3-17.

38-Elbourne DR, Prendiville WJ, Carroli G, Wood J and McDonald S (2002): Prophylactic use of oxytocin in the third stage of labor (Cochrane Review). In: The Cochrane Library, Issue 2. Oxford, UK: Update Software.

39-Dansereau J, Joshi AK, Helewa ME, et al (1999): Double-blind comparison of carbetocin versus oxytocin in prevention of uterine atony after cesarean section. *Am J Obstet Gynecol*;180(3 Pt 1):670-6.

40-Boucher M, Nimrod CA, Tawagi GF, et al (2004): Comparison of carbetocin and oxytocin for the prevention of postpartum hemorrhage following vaginal delivery: a double-blind randomized trial. *J Obstet Gynecol Can*;26(5):481-8.

41-Su LL, Chong YS and Samuel M (2007): Oxytocin agonists for preventing postpartum hemorrhage. *Cochrane Database Syst Rev*. Jul 18 ; (3):CD005457.

42-Gulmezoglu AM, Forna F, Villar J and Hofmeyr GJ (2004): Prostaglandins for prevention of postpartum hemorrhage (Cochrane Review). In: The Cochrane Library, Issue 1. Oxford, UK: Update Software.

43-Gulmezoglu AM, Villar J, Ngoc NT, et al (2001): WHO multicentre randomised trial of misoprostol in the management of the third stage of labor. *Lancet*; 358(9283):689-95.

- 44-Parsons SM, Walley RL, Crane JM, Matthews K and Hutchens D (2007):** Rectal misoprostol versus oxytocin in the management of the third stage of labour. *J Obstet Gynecol Can*;29(9):711-8.
- 45-Hamm J, Russell Z, Botha T, Carlan SJ and Richichi K (2005):** Buccal misoprostol to prevent hemorrhage at cesarean delivery: a randomized study. *Am J Obstet Gynecol*;192(5):1404-6.
- 46-Bullough CH, Msuku RS and Karonde L (1989):** Early suckling and postpartum hemorrhage: controlled trial in deliveries by traditional birth attendants. *Lancet*; 2 (8662):522-5.
- 47-Rizvi F, Mackey R, Barrett T, Mckenna P and Geary M (2004):** Successful reduction of massive postpartum hemorrhage by use of guidelines and staff education. *BJOG*; 111(5): 495-8.
- 48-Rogers J, Wood J, McCandlish R, Ayers S, Truesdale A and Elbourne D (1998):** Active versus expectant management of third stage of labour: the Hinchinbrook randomized controlled trial. *Lancet*; 351(9104):693-9.
- 49-Prendiville WJ, Elbourne D and McDonald S (2000):** Active versus expectant management in the third stage of labor (Cochrane Review). In: *The Cochrane Library*, Issue 3, and Oxford: Update Software.
- 50-Hill K, AbouZahr C and Wardlaw T (2001):** Estimates of maternal mortality for 1995. *Bull World Health Organ*; 79:182-93.
- 51-Bukowski R and Silver H (2000):** Postpartum hemorrhage. In: Evans AT, Niswander KR, eds. *Manual of Obstetrics*. 3rd ed. Philadelphia: Lippincott Williams and Wilkins; p: 482-90.
- 52-Mc Cormick ML, Sanghvi HCG, Kinzi B and McIntosh N (2002):** Preventing postpartum hemorrhage in low-resource settings. *Inter J Gynecol. Obstet*; 77: 267-75.

- 53-Jackson KW, Allbert JR and Schemmer GK (2001):** A randomized controlled trial comparing oxytocin administration before and after placental delivery in the prevention of postpartum hemorrhage. *Am J Obstet Gynecol*; 158(4): 873-7.
- 54-Sheiner E, Sarid L, Levy A, Seidman DS and Hallak M (2005):** Obstetric risk factors and outcome of pregnancies complicated with early postpartum hemorrhage: a population- based study. *J Matern Fetal Neonatal Med*; 18(3): 149-54.
- 55-Vartner M (1991):** Postpartum hemorrhage. *Critical Care Clinics*; 7(4): 883-97.
- 56-Hazra S, Chilaka V, Rajendrans and konje J (2004):** Massive postpartum hemorrhage as a cause of maternal morbidity in large tertiary hospital. *J Obstet Gynecol*; 24(5): 519-20.
- 57-Dildy GA (2002):** Postpartum hemorrhage: New management options. *Clin Obstet Gynecol*; 45(2): 330-44.
- 58-Pal M, Biswas AK and Bhattacharya SM (2003):** B-Lynch Brace suturing in primary postpartum hemorrhage during cesarean section. *J Obstet Gynecol Res*; 29: 317-20.
- 59-Ijaiya MA, Aboyaji AP and Abubakar D (2003):** Analysis of 348 consecutive cases of primary postpartum hemorrhage at a tertiary hospital in Nigeria. *J Obstet Gynecol*; 23(4): 374-7.
- 60-Arias F (1993):** Postpartum complications in practical guide to high risk pregnancy and delivery Published by Mosby-year book Inc 2nd ed. Eng. P: 433-51.
- 61-Gilstrap LC, Hauth JC, Hankins GDV and Patterson AR (1987):** Effect of type of anaesthesia on blood loss at cesarean section. *Obstet Gynecol*; 69: 328.

62-Nordstorm, Fogelstan K, Friedman G, Larsson A and Rydhstroem H (1997): Routine oxytocin in the third stage of labor. BJOG; 104: 781-786.

63-Cunningham FG, Leveno KJ, Hauth JC, Gilstrap LC and Wenstorm KD (2005): Obstetrical hemorrhage. Volume (2) Chapter 35 in Williams Obstetrics 22nd edition. Editor: P: 823-35.

64-Phillip H, Fletcher H and Reid M (2004): The impact of induced labor on postpartum blood loss. J Obstet Gynecol; 24(1): 12-5.

65-Tanaka YD, Shigemitsus M, Ichikawa Y, Sohda S, Yoshikawa H and Itai Y (2004): Postpartum MRI diagnosis of retained placenta accreta. Eur Radiol 14(6): 945-52.

66-Hussain M, Jabeen T, Liaquat N, Nooranik and Bhuttas Z (2004): Acute puerperal uterine inversion J. Call physicians Surg Pak; 14(4):215-7.

67-Myerscough P (1982): Uterine action in Labor in: Munro Kerr's operative obstetrics, 10th edition (edit) Bailnere Tindail (pub), London, P: 36-46.

68-Combs CA, Marrphy El and Larros RK (1991): Factors associated with postpartum hemorrhage with vaginal birth. Obstet Gynecol; 77: 69-76.

69-Percival R (1980): The placenta. In: Percival R, ed. Holland and Brews manual of obstetrics. 14th ed. London: J and A Churill Ltd. P: 21-4.

70-Naqvi S and Makhdoom T (2004): Conservative management of primary postpartum hemorrhage. J. Call Physicians Surg Pak; 14(5): 296-7.

71-Strand RT, Da-Silva F, Jangsten E and Bergstorm S (2005): Postpartum hemorrhage: a prospective, comparative study in Angola using a new disposable device for oxytocin administration. *Acta Obstet Gynecol Scand*; 84(3): 260-5.

72- O'Brien P, El-Refaey H, Gordon A, Geary M and Rodeck CH (1998): Rectally administered misoprostol for the treatment of postpartum hemorrhage unresponsive to oxytocin and ergometrine: a descriptive study. *Obstet Gynecol*; 92(2): 212-4.

73-Lokugamage AU, Sullivan KR, Niculescu I, et al. (2001): A randomized study comparing rectally administered misoprostol versus Syntometrine combined with an oxytocin infusion for the cessation of primary postpartum hemorrhage. *Acta Obstet Gynecol Scand*; 80 (9):835 9.

74-Vaid A, Dadhwal V, Mittal S, Deka D, Misra R and Sharma JB (2009): A randomized controlled trial of prophylactic sublingual misoprostol versus intramuscular methyl-ergometrine versus intramuscular 15-methyl PGF₂ alpha in active management of third stage of labor. *Arch Gynecol Obstet*; 80: 260-5.

75-Gulmezoglu AM, Forna F, Villar J and Hofmeyr GJ (2007): Prostaglandins for preventing postpartum hemorrhage. *Cochrane Database Syst Rev*. 07; 18; (3):CD000494.

76-Prata N, Mbaruku G, Campbell M, Potts M and Vahidnia F (2005): Controlling postpartum hemorrhage after home births in Tanzania. *Int J Gynecol Obstet*; 90(1): 51-5.

77-Caliskan E, Meydanli M, Dilbaz B, Aykan B, Sonmezer M and Hoberal A (2002): Is rectal misoprostol really effective in the treatment

of third stage of labor? A randomized controlled trial. *Am J Obstet Gynecol*; 187(4): 1038-45.

78-Condous GS and Arulkumaran S (2003): Medical and conservative surgical management of postpartum hemorrhage. *J Obstet Gynecol Can*; 25(11): 931-6.

79-Schiff PL (2006): Ergot and its alkaloids. *Am J Pharm Educ*;70: 98-107.

80-Howell,R.J.S.(1986): Hemorrhage from the placental site. *Clinics in obstetrics and gynecology*; 13 (3): 633.

81-Mantyla, R. and Kanto, J. (1981): Clinical pharmacokinetics of methylergometrine (methylergonovine). *Int J Clin Pharmacol Ther Toxicol*; 19 (9):386.

82-Iwamura, S. and Kambegawa, A. (1981): Determination of methylergometrine and dihydro ergonovine in biological fluids. *J. Pharm Dyn*; 4: 275.

83-Andersson, K.E.; Forman, A and Ulmsten, U. (1983): Pharmacology of labor. *Clinical Obstet and Gynecol*; 26 (4): 56.

84-Van-Coever den-de-Groot, H.A.; Howland, R.C. and Vader, C.G.(1982): Management of the third stage of labor in the midwife obstetric units in cape town. *S Afr Med J*; 62 (14): 478.

85-Elbourne DR, Prendiville WJ, Carroli G, Wood J and McDonald S (2001): Prophylactic use of oxytocin in the third stage of labor. *Cochrane Database Syst Rev*; (4): CD001808.

86-Kuczkowski, K.M. (2004): Myocardial ischemia induced by intramyometrial injection of methylergonovine maleate (letter). *Anesthesiology*; 100 (4): 1043.

87-Physicians' Desk Reference, 44th edition, (1990): Publisher EDWARD BARNHART.

88-Toppozada M, Baird DT, Grimes DA and Van Look P (1995): Termination of pregnancy after 14 weeks, Modern methods of inducing abortion. Oxford U.K.: Blackwell Science; 70-95.

89-Goldberg AB, Greenberg mB and Darvey PD (2001): Misoprostol and pregnancy. N Engl J Med; 344: 38-47.

90-Bauer TA, Brown D and Chai LK (1997): Vaginal misoprostol for term labor induction. Ann Pharmacother; 31:1391-3.

91-Rayburn WF (1993): A physicians prerogative to prescribe drugs for off-label uses during pregnancy. Obstet Gynecol; 81: 1052-5.

92-Southern EM (1972): Prostaglandin chemistry in the prostaglandins clinical application in human reproduction. First edition by Southern EM published by future publishing Co, New York, USA; P: 26-30.

93-Collins PW, Casey ME and Varelal (1993): Historical review of misoprostol. Contraception; 55: 330-2.

94-Costa SH (1998): Commerical availability of misoprostol and induced abortion in Brazil. Inter J of Gynecology and Obstetrics; 63(Suppl 1): S131-9.

95-Barbosa R and Ariha M(1993): The Brazilian experience with cytotec. Stud. Fam Plans; 24: 236.

96-Graham DY, White RH and Moreland LW (1993): Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAIDs. Ann Inter Med; 119: 257.

97-Collins PW (1990): Misoprostol discovery development and clinical application. Contraception; 53: 321-327.

- 98-Templeton A (1998):** Misoprostol for all?? Br J Obstet Gynecol; 105: 937-9.
- 99-Zieman M, Fong SK, Benowitz NL, Banskter D and Darney PD (1997):** Absorption Kinetic of misoprostol with oral or vaginal administration. Obstet Gynecol; 90(1): 88-92.
- 100-Khan RU, El-Refaey H, Sharma S, Sooranna D and Stafford M (2004):** Oral, rectal and vaginal pharmacokinetics of misoprostol. Obstet Gynecol; 103(5): 886-70.
- 101-Meckstroth KR, Whitaker AK, Bertisch S, Goldberg AB and Darney PD (2006):** Misoprostol administered by epithelial routes. Obstet Gynecol; 108:82-90.
- 102-Karim, A. (1988):** Pharmacokinetic profile of antiulcer prostaglandin misoprostol in human (abstract). Postgraduate Med J; 64 (Suppl. I): 80.
- 103-El-Refaey H and Templeton A (1995):** Induction of abortion in the second trimester by a combination of misoprostol and mifepristone: A randomized comparison between two misoprostol regimens. Hum Reprod; 10: 475-8.
- 104-Ho PC, Ngai SW, Liu KL, Wong G and Lee S (1997):** Vaginal misoprostol compared with oral misoprostol in termination of second trimester pregnancy. Obstet Gynecol; 90(5): 735-8.
- 105-Carbonell JLL, Varela L, Velazco A and Fernandez C (1997):** The use of misoprostol for termination of early pregnancy. Contraception; 55: 165-8.
- 106-Carbonell JLL, Varela L, Velazco A, Tanda R and Cabezas Sanchez C (1999):** Early abortion with 800 µg of misoprostol by vaginal route. Contraception; 59: 219-25.

107-Singh K, Fog YF, Prasad RN and Dong F (1999): Does an acidic medium enhance the efficacy of vaginal misoprostol for pre-abortion cervical priming. *Hum Reprod*; 14: 1635-7.

108-Feitsma AH and Kanhai HH (2005): Misoprostol in the management of postpartum hemorrhage. *International Congress Series*; 1279: 358-63.

109-Schaff EA, DiCenzo R and Fielding SL (2005): Comparison of misoprostol plasma concentrations following buccal and sublingual administration. *Contraception*; 71: 22-5.

110-Khan RU and El-Refaey H (2003): Pharmacokinetics and adverse effect profile of rectally administered misoprostol in the third stage of labor. *Obstet Gynecol*; 101(5): 968-74.

111-Cicinelli E, de Ziegler D, Bulletti C, Matteo MG, Schonauer LM and Galantino P (2000): Direct transport of progesterone from vagina to uterus. *Obstet Gynecol*; 95: 403-6.

112-Speroff, L., Glass, R.H. and Kase, N.C. (1983): *Clinical Gynecologic Endocrinology and Infertility*. Third edition. Williams and Wilkins. Baltimore and London: 307.

113-Schoenhard, G.(1985): Metabolism and pharmacokinetic studies of misoprostol. *Dig Dis Sci*; 30(suppl): 126.

114- Karim, A. (1989): Effect of food and antacid on absorption of misoprostol a synthetic prostaglandin E1 analogue. *J Clin Pharmacol*; 29:439.

115-Vogel D, Burkhardt T, Rentsch K, Schweer H, Watzer B, Zimmermann R, et al. (2004): Misoprostol versus methylergometrine: pharmacokinetics in human milk. *Am J Obstet Gynecol*; 191(6): 2168-73.



- 116- Abdel-Aleem H, Villar J, Gulmezoglu AM, Mostafa SA, Youssef AA, Shokry M, et al. (2003):** The pharmacokinetics of the prostaglandin E1 analogue misoprostol in plasma and colostrum after postpartum or administration. *Eur J Obstet Gynecol Reprod Biol* ;108: 25–8.
- 117-El-Refaey H, Calder L, Templeton A and Wheatley DN (1994):** Cervical priming with PGE1 analogues, misoprostol and gemeprost. *Lancet*; 343: 1207-9.
- 118-Michael R (2000):** Pharmacology of prostaglandin in drugs facts and comparisons. St Louis, a Wolters Kluwer Company; P: 1140-1.
- 119-Agrawal NM, Roth S and Graham DY (1991):** Misoprostol compared with sucralfate in the prevention of nonsteroidal anti-inflammatory drug-induced gastric ulcer. *Ann Inter Med*; 115:195.
- 120-Wing DA (1999):** Labor induction with misoprostol. *Am J Obstet Gynecol*; 181:339.
- 121 -Moran M, Mozes MF and Maddux MS (1991):** Prevention of acute graft rejection by the prostaglandin E1 analogue misoprostol in renal-transplant recipients treated with cyclosporine and prednisone. *NEJM*; 322: 1183-8.
- 122 -Aubeny E and Baulieu EE (1991):** Active contragestivie de la association au RU 468 Du une prostaglandin active par voie oral. *CR Acad Sci (III)*; 312: 539.
- 123-Chittacharoen A, Herabutya Y and Punyavachira P (2003):** A randomized trial of oral and vaginal misoprostol to manage delivery in cases of fetal death. *Obstet Gynecol*; 101(1): 70-3.
- 124-Chandhiok N, Dhillon BS, Datey S, Mathur A and Saxena NC (2006):** Oral misoprostol for prevention of postpartum hemorrhage by



paramedical workers in India. *International Journal of Gynecology and Obstetrics*; 92: 170-5.

125-Zachariah ES, Naidu M and Seshadri L (2006): Oral misoprostol in the third stage of labor. *Int J Gynecol Obstet*; 92(1): 23-6.

126-Nuutila M, Toivonen J, Ylikorkala O and Halmesmaki E (1997): A comparison between two doses of intra-vaginal misoprostol and gemeprost for induction of second-trimester abortion. *Obstet Gynecol*; 90: 896-900.

127-Blohm F, Friden B, Milsom I, Platz-Christensen J and Nielsen S (2005): A randomized double blind trial comparing misoprostol or placebo in the management of early miscarriage. *BJOG*; 112: 1090-5.

128-Sharma S, El-Refaey H, Stafford M, Purkayastha S, Parry M and Axby H (2005): Oral versus vaginal misoprostol administered one hour before surgical termination of pregnancy: a randomized controlled trial. *BJOG*; 112: 456-60.

129-Shetty A, Danielian P and Templeton A (2001): A comparison of oral and vaginal misoprostol tablets in the induction of labor at term. *BJOG*; 108: 106.

130-Colon I, Clawson K, Hunter K, Druzin ML and Taslimi MM (2005): Prospective randomized clinical trial of inpatient cervical ripening with stepwise oral misoprostol vs vaginal misoprostol. *Am J Obstet Gynecol*; 129(11): 747-52.

131-Rivas J and Anasti JN (2005): The effects of vaginal lubricants on insertional pain and efficacy of misoprostol for cervical ripening. *Obstet Gynecol*; 105(4): 42S.

- 132-Liu HS, Chu TY, Chang YK, Yu MH and Chen WH (1991):** Intracervical misoprostol as an effective method for labor induction. *Int J Obstet Gynecol*; 64(1): 49-53.
- 133-Srisomboon J, Piyamongkol W and Aiewsakul P (1997):** Comparison of intracervical and intravaginal misoprostol for cervical ripening and labor induction in patients with unfavorable cervix. *J Med Assoc Thai*; 80(3): 189-94.
- 134-Adekanmi OA, Purmessur S and Edwards G (2001):** Intrauterine misoprostol for the treatment of severe recurrent atonic secondary postpartum hemorrhage. *BJOG*; 108: 541-2.
- 135-Tang OS and Ho PC (2001):** Pilot study on the use of sublingual misoprostol for medical abortion. *Contraception*; 64(5): 315-7.
- 136-Vimala N, Mittal S and Kumar S (2003):** Sublingual misoprostol for preabortion cervical ripening in first trimester pregnancy termination. *Contraception*; 67(4): 295-7.
- 137-Tang OS, Lau WN, Chan CC and Ho PC (2004):** A prospective randomized comparison of sublingual and vaginal misoprostol in second trimester termination of pregnancy. *Inter J Obstet Gynecol*; 111(9): 1001-5.
- 138-Shetty A, Mackie L, Danielian P, Rice P and Templeton A (2002):** Sublingual compared with oral misoprostol in term labor induction: a randomized controlled trial. *BJOG*; 109(6): 645-50.
- 139-Wolf SB, Sanchez-Ramos L and Kauntiz AM (2005):** Sublingual misoprostol for labor induction: a randomised controlled trial. *Obstet Gynecol*; 105(2): 365-71.

- 140-Lam H, Tang OS, Lee CP and Ho PC (2004):** A pilot-randomized comparison of sublingual misoprostol with syntometrine on the blood loss in third stage of labor. *Acta Obstet Gynecol Scand*; 83(7): 647-50.
- 141-Vimala N, Mittal S, Kumar S, Dadhwal V and Mehta S (2004):** Sublingual misoprostol versus methylergometrine for active management of the third stage of labor. *Int J Gynecol Obstet*; 87(1):1-5.
- 142-Hoj L, Cardoso P, Nielson BB, Hvidman L and Aaby P (2005):** Effect of sublingual misoprostol on severe postpartum hemorrhage in a primary health centre in Guinea-Bissau: randomized double blind clinical trial. *BMJ*; 1(10): 331(7519): 723.
- 143-Vimala N, Mittal S and Kumar S (2006):** Sublingual misoprostol versus oxytocin infusion to reduce blood loss at cesarean section. *Inter J Gynecol Obstet*; 92: 106-10.
- 144-Carlan SJ, Blust D and O'Brien WF (2002):** Buccal versus intra-vaginal misoprostol administration. *Am J Obstet Gynecol*;186: 229-33.
- 145-Bhullar A, Carlan SJ, Hamm J, Lamberty N, White L and Richichi K (2004):** Buccal misoprostol to decrease blood loss after vaginal delivery: a randomized trial. *Obstet Gynecol.*; 104(6): 1282-8.
- 146-Hamm J, Russel Z, Botha T, Carlan SJ and Richichi K (2005):** Buccal misoprostol to prevent hemorrhage at cesarean delivery: A randomized study. *Am J Obstet Gynecol*; 192(5): 1404-6.
- 147-Walt RP (1992):** Misoprostol for the treatment of peptic ulcer and anti-inflammatory drug-induced gastroduodenal ulceration. *NEJM*; 327: 1575.
- 148-Aronsson A, Bygdeman M and Gemzell-Danielsson K (2004):** Effects of misoprostol on uterine contractility following different routes of administration. *Hum Reprod*; 19: 81-4.

- 149-Kulier R, Gulmezoglu AM, Hofmeyr GJ, Cheng LN and Campana A (2004):** Medical methods for first trimester abortion. *Cochrane Database Syst Rev* ;(2):CD002855.
- 150-Von Hertzen H, Piaggio G, Wojdyla D, Marions L, My Huong NT, Tang OS, et al. (2009):** Two mifepristone doses and two intervals of misoprostol administration for termination of early pregnancy: a randomised factorial controlled equivalence trial. *BJOG* ;116: 381–9.
- 151-Prasad S, Kumar A and Divya A (2009):** Early termination of pregnancy by single- dose 800 mug misoprostol compared with surgical evacuation *Fertil Steril* ;91:28–31.
- 152-Blanchard K, Shochet T, Coyaji K, Thi Nhu Ngoc N and Winikoff B (2005):** Misoprostol alone for early abortion: an evaluation of seven potential regimens. *Contraception* ;72:91–7.
- 153-Faundes A, Fiala C, Tang OS and Velasco A (2007):** Misoprostol for the termination of pregnancy up to 12 completed weeks of pregnancy. *Int J Gynecol Obstet* ;99 (Suppl 2):S172–7.
- 154-Trinder J, Brocklehurst P, Porter R, Read M, Vyas S and Smith L (2006):** Management of miscarriage: expectant, medical, or surgical? Results of randomised controlled trial (miscarriage treatment (MIST) trial). *BMJ*;332:1235–40.
- 155-Ngoc NT, Blum J, Westheimer E, Quan TT and Winikoff B (2004):** Medical treatment of missed abortion using misoprostol. *Int J Gynecol Obstet*;87:138–42.
- 156-Neilson JP, Hickey M and Vazquez J (2006):** Medical treatment for early fetal death (less than 24 weeks). *Cochrane Database Syst Rev* ; (3):CD002253.

- 157- **Sharma D, Singhal SR and Rani XX (2007):** Sublingual misoprostol in management of missed abortion in India. *Trop Doct* ;37:39–40.
- 158-**Gemzell-Danielsson K, Ho PC, Gomez Ponce de Leon R, Weeks A and Winikoff B (2007):** Misoprostol to treat missed abortion in the first trimester. *Int J Gynecol Obstet* ;99 (Suppl 2):S182–5.
- 159-**Shwekerela B, Kalumuna R, Kipingili R, Mashaka N, Westheimer E, Clark W, et al. (2007):** Misoprostol for treatment of incomplete abortion at the regional hospital level: results from Tanzania. *BJOG* ;114:1363–7.
- 160-**Dao B, Blum J, Thieb B, Raghavan S, Ouedraogo M, Lankoande J, et al. (2007):** Is misoprostol a safe, effective and acceptable alternative to manual vacuum aspiration for postabortion care? Results from a randomised trial in Burkina Faso, West Africa. *BJOG* ;114: 1368–75.
- 161-**Weeks A, Alia G, Blum J, Winikoff B, Ekwaru P, Durocher J, et al. (2005):** A randomized trial of misoprostol compared with manual vacuum aspiration for incomplete abortion. *Obstet Gynecol* ;106:540–7.
- 162-**Gemzell-Danielsson KC, Fiala C and Weeks A (2007):** Misoprostol: first-line therapy for incomplete miscarriage in the developing world. *BJOG* ;114:1337–9.
- 163-**Phupong V, Taneepanichskul S, Kriengsinyot R, Sriyirojana N, Blanchard K and Winikoff B (2004):** Comparative study between single dose 600 microg and repeated dose of oral misoprostol for treatment of incomplete abortion. *Contraception* ;70:307–11.
- 164-**Blum J, Winikoff B, Gemzell-Danielsson K, Ho PC, Schiavon R and Weeks A (2007):** Treatment of incomplete abortion and miscarriage with misoprostol. *Int J Gynecol Obstet* ;99 (Suppl 2):S186–9.

165-Grimes DA, Schulz KF, Cates WJ Jr (1984): Prevention of uterine perforation during curettage abortion. *JAMA*; 251: 2108-11.

166-MacIsaac L Grossman D, Balistreri E, Darney P (1999): A randomised controlled trial of laminaria, oral misoprostol, and vaginal misoprostol before abortion. *Obstet Gynecol*; 93: 766- 70.

167-Webster D, Penney GC, Templeton A (1996): A comparison of 600 and 200 mg mifepristone prior to second trimester abortion with the prostaglandin misoprostol. *Br J Obstet Gynecol*; 103: 706-9.

168-Ho PC, Chan YF, Lau W (1996): Misoprostol is as effective as gemeprost in termination of second trimester pregnancy when combined with mifepristone: A randomised comparative trial. *Contraception*; 53: 281-3.

169-WHO (2003): Safe Abortion: Technical and Policy Guidance for Health Systems.

170- RCOG (2004): The Care of Women Requesting Induced Abortion. London: Royal College of Obstetricians and Gynaecologists.

171- Dickinson JE and Evans SF (2002): The optimization of intravaginal misoprostol dosing schedules in second-trimester pregnancy termination. *Am J Obstet Gynecol* ;186:470–4.

172-Srisomboon J and Pongpisuttinun S (1998): Efficacy of intracervico-vaginal misoprostol in second-trimester pregnancy termination: a comparison between live and dead fetuses. *J Obstet Gynecol Res* ;24:1-5.

173-Go´mez Ponce de Leo´n R, Wing D and Fiala C (2007): Misoprostol for intrauterine fetal death. *International Journal of Gynecology and Obstetrics* ;99(Suppl 2):S190–3.

174-Hofmeyr GJ and Gulmezoglu AM (2003): Vaginal misoprostol for cervical ripening and induction of labor. *Cochrane Database Syst Rev* ;(1):CD000941.

175-Calder AA, Loughney AD, Weir CJ and Barber JW (2008): Induction of labor in nulliparous and multiparous women: a UK, multicentre, open label study of intra-vaginal misoprostol in comparison with dinoprostone. *BJOG* ;115:1279–88.

176-Wing DA, Ortiz-Omphroy G and Paul RH (1997): A comparison of intermittent vaginal administration of misoprostol with continuous dinoprostone for cervical ripening and labor induction. *Am J Obstet Gynecol* ;177:612–8.

177-Alfirevic Z and Weeks A (2009): Oral misoprostol for induction of labour. *Cochrane Database Syst Rev* ;(2):CD001338.

178-Kundodyiwa TW, Alfirevic Z and Weeks AD (2009): Low-dose oral misoprostol for induction of labor: a systematic review. *Obstet Gynecol* ;113:374–83.

179-Weeks A, Alfirevic Z, Faundes A, Hofmeyr GJ, Safar P and Wing D (2007): Misoprostol for induction of labor with a live fetus. *Int J Gynecol Obstet* ;99 (Suppl 2):S194–7.

180-Plaut MM, Schwartz ML and Lubarsky SL (1999): Uterine rupture associated with the use of misoprostol in the gravid patient with a previous cesarean section. *Am J Obstet Gynecol* ;180:1535– 42.

181-Wing DA, Lovett K and Paul RH (1998): Disruption of prior uterine incision following misoprostol for labor induction in women with previous cesarean delivery. *Obstet Gynecol* ;91:828–30.

- 182-McKenna DS, Ester JB, Proffitt M and Waddell KR (2004):** Outpatient misoprostol cervical ripening without subsequent induction of labor: a randomized trial. *Obstet Gynecol*; 104: 579-84.
- 183-Zeteroglu S, Sahin HG and Sahin HA (2005):** Induction of labor in great grandmultipara with misoprostol. *Eur J Obstet Gynecol Repord Biol*; 63: 809-14.
- 184-Porozhanova V, Sampat D and Porozhanova K (2005):** Misoprostol and induction of labor. *Akush Ginekol (Sofiia)*; 44(5): 27-30.
- 185-Khan KS, Wojdyla D, Say L, Guñmezoglu AM and Van Look PFA (2006):** WHO analysis of causes of maternal death: a systematic review. *Lancet* ;367:1066–74.
- 186-National Collaborating Centre for Women's and Children's Health (2007):** Intrapartum care. Care of healthy women and their babies during childbirth. ROCG Press:London.
- 187-Walraven G, Blum J, Dampha Y, Sowe M, Morison L, Winikoff B, et al. (2005):** Misoprostol in the management of the third stage of labour in the home delivery setting in rural Gambia: a randomised controlled trial. *BJOG* ;112:1277–83.
- 188-Derman RJ, Kodkany BS, Goudar SS, Geller SE, Naik VA, Bellad MB, et al (2006):** Oral misoprostol in preventing postpartum hemorrhage in resource-poor communities: a randomised controlled trial. *Lancet* ;368:1248–53.
- 189-WHO (2006):** WHO Recommendations for the Prevention of Postpartum Hemorrhage.
- 190-Alfirevic Z, Blum J, Walraven G, Weeks A and Winikoff B (2007):** Prevention of postpartum hemorrhage with misoprostol. *Int J Gynecol Obstet* ;99 (Suppl 2):S198–201.

191-Caliskan E, Dilbaz B, Meydanli MM, Ozturk N, Narin MA and Haberal A (2003): Oral misoprostol for the third stage of labor: a randomized controlled trial. *Obstet Gynecol*; 101(5 Pt 1):921-8.

192-Ozkaya O, Sezik M, Kaya H, Desdicioglu and Dittrich R (2005): Placebo-controlled randomized comparison of vaginal with rectal misoprostol in the prevention of postpartum hemorrhage. *J Obstet Gynecol Res*; 31(5): 389-93.

193-Baskett TF, Persad V, Clough H and Young D (2005): Prophylactic use of misoprostol in the third stage of labor. *Obstet Gynecol*; 105(4): 39S.

194-Acharya G, Al-Sammarai MT, Patel N, Al-Habib A and Kiserud T (2001): A randomised controlled trial comparing effect of oral misoprostol and intravenous syntocinon on intra-operative blood loss during cesarean section. *Acta Obstet Gynecol Scand*; 80: 245-50.

195-Bamigboye AA, Merrel DA, Hofmeyr GJ and Mitchell R (1998): Randomized comparison of rectal misoprostol with syntometrine for management of the third stage of labor. *Acta Obstet Gynecol Scand*; 77(2): 178-81.

196-Bamigboye AA, Hofmeyr GJ and Merrell DA (1998): Rectal misoprostol in the prevention of postpartum hemorrhage: a placebo-controlled trial. *Am J Obstet Gynecol*; 179: 1043-6.

197-Hofmeyr GJ, Nikodem VC, de Jager M and Gelber BR (1998): A randomized placebo controlled trial of oral misoprostol in third stage of labor. *BJOG*; 105(9): 971-5.

198-Surbek DV, Fehr PM, Hosli I and Holzgreve W (1999): Oral misoprostol for third stage of labor: a randomized placebo controlled trial. *Obstet Gynecol*; 94(2): 255-8.

- 199-Amant F, Spitz B, Timmerman D, Corremans A and Van Assche FA (1999):** Misoprostol compared with methylergometrine for the prevention of postpartum hemorrhage: a double-blind randomized trial. *BJOG*; 106: 1066-70.
- 200-El-Refaey H, Nooh R, O'Brien P, Abdalla M, Geary M, Walder J, et al. (2000):** The misoprostol third stage of labor study: a randomized controlled comparison between orally administered misoprostol and standard management. *BJOG*; 107(9): 1104-10.
- 201-Hofmeyr GJ, Ferreira S, Nikodem VC, Mangesi L, Singata M, Jafta Z, et al. (2004):** Misoprostol for treating postpartum hemorrhage: a randomized controlled trial [ISRCTN72263357]. *BMC Pregnancy Childbirth* ;4:16.
- 202-Walraven G, Dampha Y, Bittaye B, Sowe M and Hofmeyr J (2004):** Misoprostol in the treatment of postpartum hemorrhage in addition to routine management: a placebo randomised controlled trial. *BJOG* ; 111:1014–7.
- 203-Zuberi NF, Durocher J, Sikander R, Baber N, Blum J and Walraven G (2008):** Misoprostol in addition to routine treatment of postpartum hemorrhage: a hospital-based randomized-controlled trial in Karachi, Pakistan. *BMC Pregnancy Childbirth* ;8:40.
- 204-Lokugamage AU, Sullivan KR, Niculescu I, Tigere P, Onyangunga F, El Refaey H, et al. (2001):** A randomized study comparing rectally administered misoprostol versus Syntometrine combined with an oxytocin infusion for the cessation of primary postpartum hemorrhage. *Acta Obstet Gynecol Scand* ;80:835–9.

- 205-Mousa HA and Alfirevic Z (2007):** Treatment for primary postpartum hemorrhage. *Cochrane Database Syst Rev* ;(4):CD003249.
- 206-Hofmeyr GJ, Walraven G, Gulmezoglu AM, Maholwana B, Alfirevic Z and Villar J (2005):** Misoprostol to treat postpartum hemorrhage: a systematic review. *BJOG*; 112(5): 547-53.
- 207-Blum J, Alfirevic Z, Walraven G, Weeks A and Winikoff B (2007):** Treatment of postpartum hemorrhage with misoprostol. *Int J Gynecol Obstet* ;99 (Suppl 2):S202–5.
- 208- Kotsonis FN, Dodd DC, Regnier B and Kohn FE (1985):** Preclinical toxicology profile of misoprostol. *Dig Dis Sci* ;30(11 Suppl) 142S–6S.
- 209- Henriques A, Lourenco AV, Ribeirinho A, Ferreira H and Graca LM (2007):** Maternal death related to misoprostol overdose. *Obstet Gynecol* ; 109: 489–90.
- 210-Lumbiganon P, Hofmeyr J, Gulmezoglu AM, Pinol A and Villar J (1999):** Misoprostol dose-related shivering and pyrexia in the third stage of labour. *WHO Collaborative Trial of Misoprostol in the Management of the Third Stage of Labour. Br J Obstet Gynecol* ;106:304–8.
- 211-Ho PC, Blumenthal PD, Gemzell-Danielsson K, Gomez Ponce de Leon R, Mittal S and Tang OS (2007):** Misoprostol for the termination of pregnancy with a live fetus at 13 to 26 weeks. *Int J Gynaecol Obstet* ;99 (Suppl 2):S178–81.
- 212-Tang OS, Gemzell-Danielsson K and Ho PC (2007):** Misoprostol: pharmacokinetic profiles, effects on the uterus and side-effects. *Int J Gynecol Obstet* ;99 (Suppl 2):S160–7.

- 213-Fiala C, Swahn ML, Stephansson O and Gemzell-Danielsson K (2005):** The effect of non-steroidal anti-inflammatory drugs on medical abortion with mifepristone and misoprostol at 13–22 weeks gestation. *Hum Reprod* ;20:3072–7.
- 214-Hamoda H, Ashok PW, Flett GM and Templeton A (2004):** Analgesia requirements and predictors of analgesia use for women undergoing medical abortion up to 22 weeks of gestation. *BJOG* ;111:996–1000.
- 215- Kim JO, Han JY, Choi JS, Ahn HK, Yang JH, Kang IS, et al. (2005):** Oral misoprostol and uterine rupture in the first trimester of pregnancy. A case report. *Reprod Toxicol* ;20: 575–7.
- 216-Plaut MM, Schwartz ML and Lubarsky SL (1999):** Uterine rupture associated with the use of misoprostol in the gravid patient with a previous cesarean section. *Am J Obstet Gynecol* ;180: 1535–42.
- 217- Shannon C, Brothers P, Philip NM and Winikoff B (2004):** Infection after medical abortion: a review of the literature. *Contraception* ;70:183–90.
- 218- Fischer M, Bhatnagar J, Guarner J, Reagan S, Hacker JK, Van Meter SH, et al. (2005):** Fatal shock syndrome associated with *Clostridium sordellii* after medical abortion. *N Eng J Med* ;353:2352–60.
- 219-Pastuszak AL, Schuler L, Speck-Martins CE, Coelho KE, Cordello SM, Vargas F, et al. (1998):** Use of misoprostol during pregnancy and Mobius' syndrome in infants. *N Engl J Med* ;338: 1881–5.
- 220- Philip N, Shannon C and Winikoff B (2002):** Misoprostol and Teratogenicity: Reviewing the Evidence. Population Council and Gynuity Health Projects. *J Obstet Gynecol*; 158: 263-7.

221-Orioli IM and Castilla EE (2000): Epidemiological assessment of misoprostol teratogenicity. Br J Obstet Gynecol ;107:519–23.

222-Koren G, pastuszek A and Ito S (1998): Drugs in pregnancy. N Eng J med; 338: 1128.